retatrutide mechanism triple agonist gip glp-1 glucagon receptor The data just dropped — and is rewriting what's possible in obesity medicine. 🧬 TRIUMPH-1 just released Phase 3 results, and the numbers are unlike anything we've seen from a medication ADA 2026: Retatrutide Revolution

do not combine with other PDE5s

Some people may experience mild side effects such as: Temporary discomfort at the injection site Mild headache Feeling flushed These effects are usually short-lived

When you quit abruptly, ghrelin levels skyrocket , leading to intense hunger and constant thoughts about food

Before the first injection, we chatted about my weight journey as well as my medical and social history (drinking, drugs, etc.) before drawing blood to send to the lab

The Semaglutide Treatment Effect in People with Obesity (STEP) program evaluated the once-weekly administration of 2.4 mg subcutaneous semaglutide in people with obesity or overweight

Interacts with the dopaminergic system and has demonstrated cytoprotective effects on gastric mucosa, tendons, ligaments, and muscle tissue